Schizophrenia and Glutamate: An Update

Blynn Garland Bunney, Ph.D., William E. Bunney, Jr., M.D. and Arvid Carlsson


 1. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE Jr., Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187.

 2. Akbarian S, Vinuela A, Kim JJ, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances in cortical development. Arch Gen Psychiatry 1993;50:169-177.

 3. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.

 4. Arnold SE, Hyman BT, van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991;48:625-632.

 5. Borden LA, Bell SC, Ognyanov VI, et al. Glycine transport inhibitors as novel antipsychotic agents. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 200.

 6. Bosomworth PP. Ketamine symposiumócomments by moderator. Anesth Analg 1971;50:471-479.

 7. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-343.

 8. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995;674:82-90.

 9. Buchsbaum MS, Haier RJ, Potkin SG, et al. Frontostriatal disorders of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992;49:945-942.

10. Buchsbaum MS. Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Clin Neurosci 1995;3:122-130.

11. Bunney BG, Bunney WE, Jr, Carlsson A. Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York, Raven Press, 1995;1205-1214.

12. Carlsson A. The current status of the DA hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186.

13. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transm 1994;95:105-111.

14. Collinge J, Curtis D. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Brit J Psychiatry 1991;159:857-859.

15. Corssen G, Domino EF. Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine deritive Cl-581. Anesth Analg 1966;45:29-40.

16. Costa J, Khaled E, Sramek J, Bunney W, Jr., Potkin SG. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 1990;10:71-72.

17. Crosby G, Crane AM, Sokoloff L. Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiology 1982;56:437-443.

18. DeSouza DC, Abi-Saab D, Damon D, White J, Gil R, Krystal JH. Dose response of D-cycloserine, a partial NMDA-glycine site agonist, in schizophrenia. Abstract. XXth CINP Congress, Melbourne, June 23-27, 1996, No.O-22-11.

19. Davies BM, Beech HR. The effect of 1-arylcyclohexamine (Sernyl) on twelve normal volunteers. J Mental Sci 1960;106:912-924.

20. Davis DW, Mans AM, Biebuyck JF, Phil D, Hawkins RA. The influence of ketamine on regional brain glucose use. Anesthesiology 1988;69:199-205.

21. Deakin JF, Slater P, Simpson MD, et al. Frontal cortical and left temporal glutamategic dysfunction in schizophrenia. J Neurochem 1989;52:1781-1786.

22. Deutsch SI, Mastraopoalo Y, Schwartz BL, Rosse RB, Morihisa JM. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12:1-13.

23. Do KQ, Lauer CJ, Schreiber W, et al. gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995; 65:2652-2662.

24. Domino EF, Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino EF, ed. PCP (Phencyclidine): Historical and current perspectives. Michigan: NPP Books, 1981;401-418.

25. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995;29:211-223.

26. Gao XM, Shirikawa O, Tamminga CA. Delayed phencyclidine-induced alterations in local cerebral glucose utilization in rat brain. Neurosci Abs 1991;575:1473.

27. Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982;231:221-225.

28. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-1215.

29. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:12:1628-1630.

30. Goff DC, Tsai T, Levit J, Amico E, McCarley R. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 200.

31. Hammer RP, Jr, Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 1983;220:396-404.

32. Hartvig P, Valtysson J, Lindner KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58:165-173.

33. Heresco-Levy U, Javitt DC, Zukin SR. The phencyclidine/N-methyl-D-aspartate (PCP/NMDA) model of schizophrenia: Theoretical and clinical implications. Psychiatr Ann 1993;23:135-143.

34. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Brit J Psychiatry 1996;169:610-617.

35. Ishimaru M, Kurumaji A, Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 1992;32:379-381.

36. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65:303-326.

37. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.

38. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-1236.

39. Javitt D.C. Glycine and glycine uptake antagonists in the treatment of schizophrenia. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 201.

40. Johnstone M, Evans V, Baigel S. Sernyl (Cl-395) in clinical anaesthesia. J Anaesth 1959;31:433-439.

41. Judd LL, McAdams L, Budnick B, Braff DL. Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992;149:488-493.

42. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988;1:583-584.

43. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate receptor binding sites in the hippocampal formation in normal and schizophrenic postmortem brain. Neuroscience 1990;39:25-32.

44. Kerwin R. Glutamatergic abnormalities in the temporal lobe in schizophrenia. Abstract. XXth CINP Congress, Melbourne, June 23-27, 1996, No.S-30-2.

45. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 1980;20:379-382.

46. Kornhuber J, Mack-Burkhardt F, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H. 3H-MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989;77:231-236.

47. Kornhuber J, Mack-Burkhardt F, Riederer P. Regional distribution of 3H-MK-801 binding sites in the human brain. Brain Res 1989;489:397-399.

48. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatr Res 1987;20:337-345.

49. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994;51:199-214.

50. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13: 9-19.

51. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters blood flow in schizophrenia. NeuroReport 1995;6:869-872.

52. Lasagna L, Pearson JW. Analgesic and psychotomimetic properties of dexoxadrol. Proc Soc Exp Biology Med 1965;118: 352-354.

53. Li Y, Erzurumlu, Chen C, Jhaveri S, Tonegawa S. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 1994;76:427-437.

54. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 1959;81:363-369.

55. Luby ED. Phencyclidine revisited. In: Domino EF ed. PCP (Phencyclidine): Historical and current perspectives. Michigan: NPP Books,1981:425-430.

56. MacDonald JF, Mody I, Salter MW, Pennefather P, Schneiderman JH. The regulation of NMDA receptors in the central nervous system. Prog Neuro-psychopharmacol Biol Psychiatry 1989;13:481-488.

57. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-307.

58. Mansbach RS, Geyer MA. Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology 1991;105:162-168.

59. Maragos WF, Chu DCM, Greenamyre T, Penney JB, Young AB. High correlation between the localization of 3H-TCP and NMDA receptors. Eur J Pharmacol 1986;123:173-174.

60. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.

61. Nehls DG, Kurumaji A, Park CK, McCulloch J. Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neurosci Lett 1988;91:204-210.

62. Nelson SR, Howard RB, Cross RS, Samson F. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology 1980;52:330-334.

63. Nishikawa T, Takashima M, Toru M. Increased 3H-kainate acid binding in the prefrontal cortex of schizophrenics. Neurosci Lett 1983;40:245-250.

64. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982;28: 81-85.

65. Piercey MF, Ray CA. Dramatic limbic and cortical effects mediated by high affinity PCP receptors. Life Sci 1988;43:379-385.

66. Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulaskaram B: Glycine in the treatment of schizophrenia: theory and preliminary results. In Novel antipsychotic drugs. Meltzer HY (ed). New York, Raven Press, 179-188,1992.

67. Rosenbaum G, Cohen B, Luby ED, Gottlieb JS, Yelen D. Comparison of Sernyl with other drugs. Arch Gen Psychiatry 1959;1:651-656.

68. Rosse RB, Theut S, Banay-Schwartz M, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label pilot study. Clin Neuropharmacol 1989;12:416-424.

69. Rosse RB, Schwartz BL, Davis RE, Deutsch SI. An NMDA intervention strategy in schizophrenia with "low dose" milacemide. Clin Neuropharmacol 1991;14:268-272.

70. Sadove MS, Shulman M, Hatano S, Fevold N. Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg 1971;50:452-457.

71. Saija A., Princi P, DePasquale R, Costa G. Modifications of the permeability of the blood-brain barrier and local cerebral metabolism in pentobarbital- and ketamine-anaesthetized rats. Neuropharmacology 1989;28:997-1002.

72. Simopoulos AM, Pinto A, Babikow PW, Kurland A, Savage C. Psychotomimetic properties and therapeutic potentials of dexoxadrol on convalescing alcoholics. Dis Nervous Syst 1970;31:203-207.

73. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophrenia Res 1992;6:41-48.

74. Strous RD, Javitt JC. The N-methyl-D-aspartate receptor and schizophrenia. Isr J Med 1996;32:275-281.

75. Tamminga CA, Tanimoto K, Kuo S, et al. PCP-induced alterations in cerebral glucose metabolism in rat brain: Blockade by Metaphit, a PCP receptor acylating agent. Synapse 1987;1:497-504,.

76. Tamminga CA, Thanker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-530.

77. Toru M, Watanabe S, Shibuya H, et al. Neurotransmitters, receptors, and neuropeptides in postmortem brains of schizophrenics. Acta Psychiatr Scand 1988;78:121-137.

78. Tsai G, Passani LA, Slusher BS, Carter R, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-836.

79. van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996;40:1298-1300.

80. Waziri R: Glycine therapy of schizophrenia. Biol Psychiatry 1988; 23:210.

81. Waziri R, Baruah S, Sherman AD. Abnormal serine-glycine metabolism in the brains of schizophrenics. Neurosci Lett 1992;120:237-240.

82. Weissman AD, Dam M, London ED. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 1987;435:29-40.

83. Weissman AD, Casanova MF, Kleinman E, London ED, DeSouza EB. Selective loss of cerebral sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.

84. Weissman AD, Casanova MF, Kleinman JE, and DeSouza EB. PCP and sigma receptors in brain are not altered after repeated exposure to PCP in humans. Neuropsychopharmacology 1991;4:95-102.

85. Williams MW, Williford WA, Williams CS, Towne JC. Clinical analgesic activity of dexoxadrol. Arch Int Pharmacodyn 1969;178:26-30.

Back to Chapter

published 2000